Last Updated: 19 Sep 2024
Executive Summary
Novo Integrated Sciences Inc. (NVOS) is a healthcare services provider headquartered in Bellevue, Washington. The company has a market capitalization of $607 million and trades on the NASDAQ exchange. NVOS has been facing financial challenges, with negative earnings and margins. Its latest stock price is $0.33, close to its 52-week low of $0.20.
Company Overview
NVOS provides primary healthcare services, including primary care, urgent care, and occupational medicine. The company operates a network of clinics in the Pacific Northwest region of the United States. NVOS has been expanding its operations through acquisitions and partnerships.
Fundamental Analysis
Revenue: NVOS's revenue has been declining in recent quarters. In the latest quarter, revenue was $13.5 million, down 4.3% year-over-year.
Earnings: NVOS has been reporting negative earnings for several quarters. In the latest quarter, the company reported a net loss of $1.3 million.
Margins: NVOS's profit margin and operating margin are both negative, indicating that the company is struggling to generate profits.
Book Value: NVOS's book value per share is $0.523.
Debt: NVOS has $11.5 million in long-term debt.
Technical Analysis
Price Action: NVOS's stock price has been trending down in recent months. The stock is currently trading below its 50-day and 200-day moving averages.
Support and Resistance: The stock has support at $0.20 and resistance at $0.50.
Momentum: NVOS's momentum indicators are negative, indicating that the stock is in a downtrend.
Short Term Outlook
In the short term, NVOS's stock price is likely to continue to decline. The company is facing financial challenges and its stock is trading below its key moving averages.
Long Term Outlook
In the long term, NVOS's outlook is uncertain. The company needs to improve its financial performance and generate positive earnings in order to sustain its operations.
Analyst Recommendations
Analysts have a negative outlook on NVOS. They believe that the company's financial challenges will continue to weigh on its stock price.
